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Previewswith their modified protocol satisfied all
molecular and functional tests of pluripo-
tency, thus validating their identity. More-
over, in addition to their capacity to
generate progeny from all three germ
layers, RiPSC exhibited advantages rela-
tive to iPSCs obtained by viral delivery
of RFs, given that they displayed: (1)
a fast 2 week output, (2) greater homoge-
neity, and (3) a global molecular signa-
ture that clustered closer to those of
human embryonic stem cells (hESCs).
Although the long-term implications of
the findings that RiPSCs arise more
frequently and homogeneously—and with
faster kinetics—remain to be seen, the
final point emphasizes the crucial impor-
tance of using hESCs as the gold stan-
dard by which to measure the results of
comparative studies among sources of
pluripotent cells.
Also, the findings of this study demon-
strate the feasibility of the RNA-mediated
approach to support directed differentia-
tion, given that introduction of modified,
synthetic mRNA for MyoD was able to
convert RiPSCs or mesenchymal stem
cells into myotubes (Warren et al., 2010).
Further application of this technology will
lead to the simplification of RNA-medi-
ated differentiation of target cells toward
specific, desired cell fates.550 Cell Stem Cell 7, November 5, 2010 ª20Another route to change fate of one cell
into another, involves transdifferentiation,
of somatic cells without passing through
an embryonic state. This strategy was
originally utilized when ectopic expres-
sion of a single transcription factor,
MyoD, led to the transdifferentiation of
fibroblasts into terminally differentiated
myofibers (Davis et al., 1987). The parallel
approach has since been applied to
a variety of cells, such as the in vivo
conversion of mouse pancreatic exo-
crine cells to pancreatic b cells after the
delivery of three factors (Ngn3, Pdx1,
and Mafa; Zhou et al., 2008). Thus, trans-
differentiation may provide yet another
platform for cell-based therapy strategies
in clinical settings. It will be interesting to
assess whether the synthetic mRNA tech-
nology could be applied to transdifferenti-
ate adult somatic cells into useful cell
types.
The use of synthetic mRNAs to change
cell fate has come a long way since its
debut in the amphibian system. The inge-
nious adaptation of this technology to the
human system in order tomediate reprog-
ramming and directed differentiation,
including the additional problem solving
conducted by the authors in order to
derive integration-free RiPSCs, makes
the modified RNA approach a powerful10 Elsevier Inc.new tool that brings cell-based therapy
ever closer to reality.REFERENCES
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Mammalian cloning by somatic cell nuclear transfer is a notoriously inefficient process with a low birth rate.
Recently in Science, Inoue et al. (2010) report that somatic cell nuclear transfer fails to regulate Xist expres-
sion from the X chromosome.Three broad categories encompass the
varied experimental approaches used to
reprogram somatic nuclei to a pluripotent
state: cell fusion between somatic and
embryonic stem cells (ESCs), transcrip-
tion-factor transduction, and somatic
cell nuclear transfer (SCNT). Cell fusionhas been useful for exploring the regula-
tory mechanisms responsible for reprog-
ramming; however, the tetraploid nature
of fused cells prevents a stringent
in vivo test of the cell’s developmental
potential. On the other hand, induced
pluripotent stem cells (iPSCs) generatedby defined transcription-factor transduc-
tion have been successfully assayed for
their ability to generate completely stem
cell-derived embryo proper by tetraploid
embryo complementation. SCNT repro-
grams somatic cell nuclei through nuclei
introduction into enucleated oocytes,
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Figure 1. Ectopic Xist Activity Hinders SCNT Reprogramming
Inoue and colleagues have shown that SCNT-derived blastocysts (blue line)
exhibit ectopic Xist expression (pink) and often fall short of generating live
offspring. Derivation of ntESCs from the SCNT blastocysts (dashed blue
line) improves success rates of live pup birth from tetraploid embryo comple-
mentation. Xist-deficient SCNT produces blastocysts (red line) with a higher
rate of live pup birth.
In comparison to SCNT, the generation of iPSC clones (green line) is a pro-
longed process and it remains to be explored whether Xist is properly
repressed during this period. Many reprogramming clones fail to become
transgene-independent iPSCs and do not contribute to the germline in cloned
mice.
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Previewsculminating in the live birth of
a cloned organism.
Successful nuclear reprog-
ramming requires erasure of
the donor nuclei’s epigenetic
pattern and the re-establish-
ment of embryonic epigenetic
characteristics and gene ex-
pression in the cloned em-
bryo. Mammalian embryos
derived by SCNT progress to
the blastocyst stage of devel-
opment with an efficiency of
30%–50%, which is compa-
rable to that of embryos
derived by in vitro fertilization.
However, in contrast with
fertilization-derived embryos,
a large number of cloned
embryos die during postim-
plantation development, with
a survival rate to birth for
cloned blastocysts of approx-
imately 1%–5%.
In mammals, X chromo-some inactivation (XCI) represses one of
two X chromosomes in female cells to
ensure that X-linked gene expression
levels are comparable to that of male
cells. XCI is best studied in the mouse,
where both X chromosomes are active in
the preimplantation female embryos,
followed by random XCI of either the
paternal or maternal X chromosome in
the postimplantation embryo proper. Initi-
ation of XCI is dependent on the noncod-
ing RNA Xist, which becomes expressed
in the future inactive X chromosome (Xi).
Xist RNA spreads along the expressing X
chromosome to initiate silencing, fol-
lowed by the accumulation of repressive
chromatinmarks. In contrast, Xist remains
silent in the active X (Xa). Reactivation of
the Xi is an important event during the
reprogramming of female somatic cells,
either by NT or defined factors. The signif-
icance of X chromosome activation during
reprogramming was amatter of investiga-
tion in a recent Science report (Inoue
et al., 2010).
In their study, the authors focused on
identifying common (nonrandom) epige-
netic errors that arise during SCNT, by
comparing global gene expression in
cloned blastocysts and genotype-
matched IVF blastocysts (Inoue et al.,
2010). Genome-wide expression abnor-
malities specific to each donor cell type
were observed, and further in-depthanalysis of gene expression profiles re-
vealed that 21 out of 39 commonly down-
regulated genes are located on the X
chromosome (Inoue et al., 2010). They
observed that SCNT embryos are not
able to suitably repress Xist activity;
ectopic Xist expression was present in
both male and female preimplantation
embryos as early as the 4-cell stage. By
using Xist-deficient donor nuclei, the
authors showed that this ectopic expres-
sion of Xist in cloned blastocysts contrib-
uted to the downregulation of half of the
affected X-linked genes. Interestingly,
genes linked to Magea and Xlr regions of
the X chromosome were found to be
downregulated by an alternate mecha-
nism: the failure of reprogramming
repressive histone modification of these
regions.
By using Xist-deficient donor nuclei for
SCNT to prevent inappropriate XCI and
thereby restoring normal X-linked gene
expression, the authors observed a
genome-wide effect that limited the
number of downregulated autosomal
genes by 85% and 73% in female and
male embryos, respectively. The ‘‘refur-
bished’’ gene expression levels had a
dramatic effect on the efficiency of gen-
erating viable cloned animals, which
reached more than 10%, corresponding
to 8- to 9-fold higher success rate when
compared to wild-type controls.Cell Stem Cell 7, November 5As often happens with
important discoveries, Inoue
et al.’s findings raise more
questions than they answer.
It is of particular interest to
determine whether these re-
programming errors are also
observed in ESCs that can
be derived from the SCNT
blastocysts (ntESCs). Main-
taining cultured cells in a plu-
ripotent state as a ntESC line
may facilitate the correction
of the initial epigenetic errors
observed in the SCNT blasto-
cysts. In support of this hy-
pothesis, the success rate of
generating viable pups from
SCNT is significantly elevated
when ntESCs are derived
from the cloned blastocyst
and then tetraploid embryo
complementation was used
to produced cloned animals
(Hochedlinger and Jaenisch,2002). This increase in cloning success
may stem from improved, consistent
global reprogramming of the donor
genome during the ntESC derivation pro-
cess (Figure 1). Alternatively, the exclu-
sion of ntESC contribution to tetraploid
embryo complementation extra-embry-
onic tissues might overcome some of
the incomplete reprogramming status of
the donor nuclei. Monitoring ectopic Xist
expression during ntESCderivation would
help shed light on this question.
Reprogramming of mouse female
somatic cells by defined transcription
factors reactivates the inactive X chromo-
some so that mouse iPSCs possess two
active X chromosomes (Maherali et al.,
2007). In light of the results from Inoue
and colleagues, it would be interesting
to examine the dynamics of Xi reactivation
and the completeness of Xist shut down
during female iPSC formation, as well as
to determine whether ectopic Xist expres-
sion is observed at any point during the
reprogramming of male cells. The predic-
tion is that Xist is not expressed at any
point during the reprogramming of male
iPSCs, because the mechanism(s) attrib-
uted to ectopic Xist expression during
SCNTmay not be active during iPSC deri-
vation. If true, the efficiency of cloning
animals with an intact Xist gene might
also be improved by first deriving iPSCs
from somatic cells, and by using the, 2010 ª2010 Elsevier Inc. 551
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Previewsresulting reprogrammed cells as nuclei
donors for NT.
Although the kinetics of X inactivation is
well characterized during mouse devel-
opment, this process is less defined for
early human development. Undifferenti-
ated human ESC lines exhibit conflicting
signs of XCI, in a cell line- and passage-
specific manner. The observed disparities
may be a consequence of different ESC
derivation techniques and maintenance
conditions of the pluripotent lines. For
example, Lengner et al. reported that
under conditions of physiological oxygen
(in vitro hypoxic conditions), it is possible
to derive female human ESCs that exhibit
two active X chromosomes, as observed
in mouse ESCs (Lengner et al., 2010).
Exposure of these XaXa human ESC lines
to atmospheric oxygen induced XCI, and
once XCI was initiated in hESCs, culture
in hypoxic conditions did not reactivate
the X chromosome. This outcome sug-
gests that standard culture conditions
for hESC maintenance are not conducive
for retaining two active X chromosomes.
It has been reported recently that
during the reprogramming of human fibro-
blasts to iPSCs, the inactive X chromo-
some does not reactivate at any point.
This model is supported by the observa-
tion that XCI is clonal within human iPSC552 Cell Stem Cell 7, November 5, 2010 ª20lines, in that the original fibroblast Xi chro-
mosome does not reactivate during
reprogramming and remains inactive in
all differentiated derivatives of the iPSCs
(Tchieu et al., 2010). Another recent report
demonstrated that human pluripotent
stem cells can be reprogrammed to, and
maintained in, a so-called naive state
that shares traits with mouse ESCs
(Hanna et al., 2010). These naive hESCs
morphologically resemble mouse ESCs,
possess high cloning efficiencies, and
notably lack Xist clouds (Hanna et al.,
2010). These findings further support the
ever-strengthening notion that human
ESCs correspond to a more develop-
mentally advanced cell type than that
represented by mouse ESCs, possibly
the postimplantation epiblast where XCI
has already occurred.
Gene expression data sets exist for
mouse and human ESCs, iPSCs, and
corresponding fibroblast cells. What
needs to be determined is whether the
reprogramming process is impeded by
inappropriate expression of Xist. In our
experience, the efficiency of live births by
diploid aggregation and tetraploid com-
plementation of mouse iPSCs is reduced
when compared with mouse ESCs—
ectopic Xist expression and abhorrent
XCI may in part hold the answer.10 Elsevier Inc.The low frequency of live births from
SCNT blastocysts suggests that the
fidelity of nuclear reprogramming is
incomplete. The discovery that ectopic
Xist expression contributes to this aber-
rant expression pattern will surely initiate
a new wave of research to supply solu-
tions to this challenge.REFERENCES
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